Ultragenyx tumbles on $400 mln Crysvita royalty sale

Ultragenyx Pharmaceutical

04/11/2025 22:40

** Shares of drugmaker Ultragenyx Pharmaceutical RARE.O fall 12% to $28.64 in extended trading

** Ultragenyx says it has sold an additional 25% of its future royalty interest in Crysvita to Canadian pension fund OMERS for $400 million

** OMERS will begin receiving the added royalty share from Crysvita sales in the U.S. and Canada starting in January 2028

** Crysvita, approved in 2018 to treat a rare bone disorder, has generated more than $4 billion in cumulative sales in the region since launch - Ultragenyx

** Stock down 23% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))